Nepafenac
Clinical data | |
---|---|
Trade names | Nevanac |
AHFS/Drugs.com | Monograph |
MedlinePlus | a606007 |
Pregnancy category |
|
Routes of administration | Ophthalmic |
ATC code | S01BC10 (WHO) |
Legal status | |
Legal status |
|
Identifiers | |
| |
PubChem (CID) | 151075 |
IUPHAR/BPS | 7564 |
DrugBank | DB06802 |
ChemSpider | 133160 |
UNII | 0J9L7J6V8C |
KEGG | D05143 |
ChEBI | CHEBI:75922 |
ChEMBL | CHEMBL1021 |
ECHA InfoCard | 100.207.414 |
Chemical and physical data | |
Formula | C15H14N2O2 |
Molar mass | 254.28 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
(what is this?) (verify) |
Nepafenac is a non-steroidal anti-inflammatory drug (NSAID), usually sold as a prescription eye drop 0.1% solution. Nepafenac is manufactured by Alcon and sold under the trade name Nevanac. It is used to treat pain and inflammation associated with cataract surgery.[1]
The usual dose is one drop, thrice a day, in each affected eye beginning one day prior to cataract surgery, continued on the day of surgery and through the first two weeks of the postoperative period.[1]
Nepafenac is a prodrug of amfenac, an inhibitor of COX-1 and COX-2 activity.[2][3] Its side effects may include decreased visual acuity, a feeling that something is in the eye, increased eye pressure or a sticky sensation, as well as other effects.[1]
Brand names of Nepafenac include Ilevro and Nevanac.
References
- 1 2 3 Nepafenac Monograph
- ↑ Drugbank: Nepafenac
- ↑ Lira, R. P.; Fulco, E. A.; Chaves, A.; Da Costa Pinto, F.; Arieta, F. R.; Lira, C. E. (2012). "Effect of preoperative use of topical prednisolone acetate, ketorolac tromethamine, nepafenac and placebo, on the maintenance of intraoperative mydriasis during cataract surgery: A randomized trial". Indian Journal of Ophthalmology. 60 (4): 277–281. doi:10.4103/0301-4738.98705. PMC 3442462. PMID 22824596.